Endothelial function and its assessment

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1319-1336

  Felmeden, Dirk C ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Assessment; Cilatation; Endothelial function; Flow mediated

Indexed keywords

AMLODIPINE; ATENOLOL; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CANDESARTAN; CARVEDILOL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ESTROGEN; IRBESARTAN; LACIDIPINE; LISINOPRIL; LOSARTAN; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NIFEDIPINE; NITRIC OXIDE; PERINDOPRIL; PLASMINOGEN ACTIVATOR INHIBITOR 1; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VON WILLEBRAND FACTOR;

ATHEROSCLEROSIS; BLOOD CLOTTING; BLOOD VESSEL PERMEABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; ENDOTHELIUM; FUNCTIONAL ASSESSMENT; HUMAN; HYPERTENSION; NON INVASIVE MEASUREMENT; NONHUMAN; PATHOPHYSIOLOGY; PROVOCATION TEST; REVIEW; RISK ASSESSMENT; TARGET ORGAN; THROMBOCYTE; THROMBOSIS; TISSUE INJURY; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ARGININE; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE; STEM CELLS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE-1; VASODILATION; VON WILLEBRAND FACTOR;

EID: 27744452963     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1319     Document Type: Review

References (248)

1. MONCADA S, HIGGS A: The L-arginine-NO-pathway. N. Engl. J. Med. (1993) 329:2002-2020.
2. COHEN R: The role of nitric oxide and other endothelium derived vasoactive substances in vascular disease. Prog. Cardiovasc. Dis. (1995) 38:105-128.
3. LUESCHER TF, NOLL G: Endothelial dysfunction in the coronary circulation. J. Cardiovasc. Pharmacol. (1994) 24(Suppl. 3):S16-S26.
4. YANAGISAWA M, KURIHARA H, KIMURA S et al.: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332:411-415.
5. DREXLER H: Endothelial dysfunction: clinical implications. Prog. Cardiovasc. Dis. (1997) 39(4):287-324.
6. CLARKSON P, CELERMAJER DS, DONALD AE et al.: Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. (1996) 28(3):573-579.
7. LUDMER PL, SELWYN AP, SHOOK TL et al.: Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic arteries. N. Engl. J. Med. (1986) 315:1046-1051.
8. ENDERLE MD, BENDA N, SCHMUELLING RM, HAERING HU, PFOHL M: Preserved endothelial function in IDDM patients, but not in NIDDM patients, compared with healthy subjects. Diabetes Care (1998) 21(2):271-277.
9. ENDERLE MD, PFOHL M, KELLERMANN N, HAERING HU, HOFFMEISTER HM: Endothelial function, variables of fibrinolysis and coagulation in smokers and healthy controls. Haemostasis (2000) 30(3):149-158.
10. PANZA JA, QUYYUMI AA, BRUSH JE Jr, EPSTEIN SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. (1990) 323(1):22-27.
11. PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 333:664-666.
12. BREDT DS, HWANG PM, GLATT CE, LOWENSTEIN C, REED RR, SNYDER SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P450 reductase. Nature (1991) 351:714.
13. FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 299:373-376.
14. VALLANCE P, COLLIER V, MONCADA S: Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 2:997-1000.
15. QUYYUMI AA, DAKAK N, ANDREWS NP, GILLIGAN DM, PANZA JA, CANNON ROR: Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation (1995) 92:320-326.
16. POHL U, HOLTZ J, BUSSE R, BASSENGE E: Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension (1986) 8:37-44.
17. LUESCHER TF, VANHOUTTE PM: The endothelium: modulator of cardiovascular function. CRC Press, Florida, USA (1990).
18. LUESCHER TF, BOULANGER CM, YANG Z, NOLL G, DOHI Y: Interactions between endothelium-derived relaxing and contracting factors in health and cardiovascular disease. Circulation (1993) 87:36-44.
19. KUBES P, SUZUKI M, GRANGER DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA (1991) 81:4651-4655.
20. DAVIES MJ, GORDON JL, GEARING AJ et al.: The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J. Pathol. (1993) 171:223-229.
21. SAKAI A, KUME N, NISHI E, TANOUE K, MIYASAKA M, KITA T: P-selectin and vascular cell adhesion molecule-1 are focally expressed in aortas of hypercholesterolemic rabbits before intimal accumulation of macrophages and T lymphocytes. Arterioscler. Thromb. Vasc. Biol. (1997) 17:310-316.
22. ROSS R: Atherosclerosis: an inflammatory disease. N. Engl. J. Med. (1999) 340:115-126.
23. LIBBY P: Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am. J. Cardiol. (2000) 86:3J-8J.
24. RIDKER PM, HENNEKENS CH, ROITMAN-JOHNSON B, STAMPFER MJ, ALLEN J: Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet (1998) 351(9096):88-92.
25. RADOMSKI MW, PALMER RM, MONCADA S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 2(8567):1057-1058.
26. MICHELSON AD, BENOIT SE, FURMAN MI et al.: Effects of nitric oxide/EDRF on platelet surface glycoproteins. Am. J. Physiol. (1996) 270(5 Part 2):H1640-H1648.
27. KADER KN, AKELLA R, ZIATS NP et al.: eNOS-overexpressing endothelial cells inhibit platelet aggregation and smooth muscle proliferation in vitro. Tissue Eng. (2000) 6:241-251.
28. PEARSON JD: Endothelial cell function and thrombosis. Baillieres Best Pract. Res. Clin. Haematol. (1999) 12:329-341.
29. PEARSON JD: Normal endothelial cell function. Lupus (2000) 9:183-188.
30. SEIGNEUR M, DUFOURCO P, CONRI C et al.: Plasma thrombomodulin: new approach of endothelium damage. Int. Angiol. (1993) 12:355-359.
31. RUBANYI GM: The role of endothelium in cardiovascular homeostasis and disease. J. Cardiovasc. Pharmacol. (1993) 22(Suppl. 4):S1-S14.
32. DZAU VJ, GIBBONS GH: Endothelium and growth factors in vascular remodeling in hypertension. Hypertension (1991) 18(Suppl. III):III-115-III-121.
33. BOBIK A, CAMPBELL JH: Vascular derived growth factors: cell biology, pathophysiology and pharmacology. Pharmacol. Rev. (1993) 45:1-42.
34. CASTELLOT JJ, ADDONIZIO ML, ROSENBERG RD, KARNOWSKY MJ: Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle growth. J. Cell Biol. (1981) 90:372-379.
35. BOBIK A, GROOMS A, MILLAR JA, MITCHELL A, GRINPUNKEL S: Growth factor activity of endothelin on vascular smooth muscle. Am. J. Physiol. (1990) 258:C408-C415.
36. JANAKIDEVI K, FISHER MA, DEL VECCHIO PJ, TIRUPPATHI C, FIGGE J, MALIK AB: Endothelin-1 stimulates DNA synthesis and proliferation of pulmonary artery smooth muscle cells. Am. J. Physiol. (1992) 263:C1295-C1301.
37. SHIROTANI M, YUI Y, HATTORI R, KAWAI C: U-61, 431F, a stable prostacyclin analogue, inhibits the proliferation of bovine vascular smooth muscle cells with little antiproliferative effect on endothelial cells. Prostaglandins (1991) 41:97-110.
38. ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801-809.
39. RUBANYI GM, POLOKOFF MA: Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. (1994) 46:325-415.
40. VITA JA, TREASURE CB, NABEL EG et al.: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation (1990) 81:491-497.
41. SCHACHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator function on adverse long-term outcome of coronary heart disease. Circulation (2000) 101:1899-1906.
42. HEITZER T, SCHLINZIG T, KROHN K, MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104(22):2673-2678.
43. LIP GYH, BLANN A: von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc. Res. (1997) 34:255-365.
44. BLANN A: von Willebrand factor and the endothelium in vascular disease. Br. J. Biomed. Sci. (1993) 50:125-134.
45. BLANN AD, TABERNER DA: A reliable marker of endothelial cell dysfunction: does it exist? Br. J. Haematol. (1995) 90:244-248.
46. BOWIE EJW, SOLBERG LA, FASS DN et al.: Transplantation of normal bone marrow into a pig with severe von Willebrand disease. J. Clin. Invest. (1986) 78:26-30.
47. VAN MOURIK JA, BOERTJES R, HUISVELD IA et al.: von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial perturbation. Blood (1999) 94:179-185.
48. HIROKAWA K, AOKI N: Up-regulation of thrombomodulin in human umbilical vein endothelial cells in vitro. J. Biochem. (1990) 108:839-845.
49. POTTINGER BE, READ RC, PALEOLOG EG, HIGGINS PG, PEARSON JD: von Willebrand factor is an acute phase reactant in man. Thromb. Res. (1989) 53:387-394. 73:1586-91.
50. HAINES AP, HOWARTH D, NORTH WR et al.: Haemostatic variables and the outcome of myocardial infarction. Thromb. Haemost. (1983) 50:800-803.
51. JANSSON J, NILSSON TK, JOHNSON O: von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br. Heart J. (1991) 66:351-355.
52. MEADE TW, COOPER JA, STIRLING Y, HOWARTH DJ, RUDDOCK V, MILLER GJ: Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br. J. Haematol. (1994) 88:601-607.
53. BICKEL C, RUPPRECHT HJ, BLANKENBERG S et al.: Relation of markers of inflammation (C-reactive protein, fibrinogen, von Willebrand factor, and leukocyte count) and statin therapy to long-term mortality in patients with angiographically proven coronary artery disease. Am. J. Cardiol. (2002) 89:901-908.
54. G-dimethyl-L-arginine to L-citrulline in rars. Biochem. Biophys. Res. Commun. (1987) 148:671-677.
55. G-dimethyl-arginine, N-mono-, di-, and trimethyllysine, and glucosylgalactosyl-, and galactosyl-δ-hydroxylysine from human urine. J. Biol. Chem. (1970) 245:5751-5758.
56. VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 339:572-575.
57. MATSUOKA H, ITOH S, KIMOTO M et al.: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension (1997) 29:242-247.
58. BOEGER RH, BODE-BOGER SM, SZUBA A et al.: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation (1998) 98:1842-1847.
59. MIYAZAKI H, MATSUOKA H, COOKE JP et al.: Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation (1999) 99:1141-1146.
60. ABBASI F, ASAGMI T, COOKE JP et al.: Plasma concentrations of asymmetric dimethylarginine are increased in patients with Type 2 diabetes mellitus. Am. J. Cardiol. (2001) 88:1201-1203.
61. STUHLINGER MC, ABBASI F, CHU JW et al.: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA (2002) 287:1420-1426.
62. COOKE JP: Does ADMA cause endothelial dysfunction? Arterioscler. Thromb. Vasc. Biol. (2000) 20:2032-2037.
63. ITO A, TSAO PS, ADIMOOLAM S, KIMOTO M, OGAWA T, COOKE JP: Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation (1999) 99:3092-3095.
64. COOKE JP, ANDON NA, GIRERD XJ, HIRSCH AT, CREAGER MA: Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta. Circulation (1991) 83:1057-1062.
65. COOKE JP, DZAU VJ: Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation (1997) 96:379-382.
66. CREAGER MA, GALLAGHER SJ, GIRERD XJ, COLEMAN SM, DZAU VJ, COOKE JP: L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J. Clin. Invest. (1992) 90:1248-1253.
67. DREXLER H, FISCHELL TA, PINTO FJ et al.: Effect of L-arginine on coronary endothelial function in cardiac transplant recipients: relation to vessel wall morphology. Circulation (1994) 89:1615-1623.
68. MASAKI T, VANE JR, VANHOUTTE PM: International Union of Pharmacology nomenclature for endothelin receptors. Pharmacol. Rev. (1994) 46:137-142.
69. SPIEKER LE, NOLL G, RUSCHITZKA FT, LUSCHER TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol. (2001) 37:1493-1505.
70. ARAI H, HORI S, ARAMORI I, OHKUBO H, NAKANISHI S: Cloning and expression of a cDNA encoding an endothelin receptor. Nature (1990) 348:730-732.
71. SCHINI VB, VANHOUTTE PM: Endothelin-1: a potent vasoactive peptide. Pharmacol. Toxicol. (1991) 69:1-7.
72. B recetors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 89:1203-1208.
73. VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 97:752-756.
74. YOSHIZUMI M, KURIHARA H, MORITA T et al.: Interleukin 1 increases the production of endothelin-1 by cultured endothelial cells. Biochem. Biophys. Res. Commun. (1990) 166:324-329.
75. YOSHIZUMI M, KURIHARA H, SUGIYAMA T et al.: Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem. Biophys. Res. Commun. (1989) 161:859-864.
76. KOUREMBANAS S, MARSDEN PA, McQUILLAN LP, FALLER DV: Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J. Clin. Invest. (1991) 88:1054-1057.
77. HAYNES WG, WEBB DJ: Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. (1998) 16:1081-1098.
78. MORISE T, TAKEUCHI Y, KAWANO M, KONI I, TAKEDA R: Increased plasma levels of immunoreactive endothelin and von Willebrand factor in NIDDM patients. Diabetes Care (1995) 18:87-89.
79. COLUCCI WS: Myocardial endothelin: does it play a role in myocardial failure? Circulation (1996) 93:1069-1072.
80. SELIGMAN BG, BIOLO A, POLANCZYK CA, GROSS JL, CLAUSELL N: Increased plasma levels of endothelin 1 and von Willebrand factor in patients with Type 2 diabetes and dyslipidaemia. Diabetes Care (2000) 23:1395-1400.
81. FLAVAHAN N, VANHOUTTE PM: Endothelial cell signalling and endothelial dysfunction. Am. J. Hypertens. (1995) 8(Suppl. 5):28S-41S.
82. BOULANGER CM, TANNER FC, BEA ML, HAHN AWA, WERNER A, LUESCHER TF: Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ. Res. (1992) 70:1191-1197.
83. BOHM F, AHLBORG G, PERNOW J: Endothelin-1 inhibits endothelium-dependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin. Sci. (2002) 102(3):321-327.
84. DAVIES MG, HAGEN P-O: The vascular endothelium: a new horizon. Ann. Surg. (1993) 218:593-609.
85. CYBULSKY MI, GIMBRONE MA Jr: Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science (1991) 251:788-791.
86. LI H, CYBULSKY MI, GIMBRONE MA Jr, LIBBY P: An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler. Thromb. (1993) 13:197-204.
87. O'BRIEN KD, ALLEN MD, McDONALD TO et al.: Vascular cell adhesion molecule-1 is expressed in human coronary atherosclerotic plaques: implications for the mode of progression of advanced coronary atherosclerosis. Circulation (1993) 92:945-951.
88. DE CATERINA R, BASTA G, LAZZERINI G et al.: Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1997) 17:2646-2654.
89. MALMQVIST K, WALLEN HN, HELD C, KAHAN T: Soluble cell adhesion molecules in hypertensive concentric left ventricular hypertrophy. J. Hypertens. (2002) 20(8):1563-1569.
90. GASIC S, WAGNER OF, FASCHING P et al.: Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive Type II diabetic patients with microalbuminuria. Am. J. Hypertens. (1999) 12(2 Part 1):217-222.
91. GEARING AJ, NEWMAN W: Circulating adhesion molecules in disease. Immunol. Today (1993) 14:506-512.
92. PIGOTT R, DILLON LP, HEMINGWAY IH, GEARING AJ: Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants and cytokine activated cultured endothelial cells. Biochem. Biophys. Res. Commun. (1992) 187:584-589.
93. BLANN AD, LIP GYH: The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul. Fibrinolysis (1998) 9:297-306.
94. BLANN AD, TSE W, MAXWELL SJ, WAITE MA: Increased levels of the soluble adhesion molecule E-selectin in essential hypertension. J. Hypertens. (1994) 12:925-928.
95. BLANN AD, WAITE MA: von Willebrand factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron. Artery Dis. (1996) 7:143-147.
96. ALEXIOU D, KARAYIANNAKIS AJ, SYRIGOS KN et al.: Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur. J. Cancer (2001) 37:2392-2397.
97. BLANKENBERG S, RUPPRECHT HJ, BICKEL C et al.: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation (2001) 104:1336-1342.
98. BRAMAN RS, HENDRIX SA: Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal. Chem. (1989) 61(24):2715-2718.
99. 15N-labelled analogs. J. Chromatogr. B. Biomed. Appl. (1994) 661(2):185-191.
100. BOLOTINA VM, NAJIBI S, PALACINO JJ, PAGANO PJ, COHEN RA: Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature (1994) 368(6474):850-853.
101. 3-excretion as an indicator of nitric oxide formation in vivo during oral administration of L-arginine or L-NAME in rats. Clin. Exp. Pharmacol. Physiol. (1996) 23:11-15.
102. VIINIKKA L: Nitric oxide as a challenge for the clinical chemistry laboratory. Scand. J. Clin. Lab. Invest. (1996) 56(7):577-581.
103. FICHTLSCHERER S, ZEIHER AM: Endothelial dysfunction in acute coronary syndromes: association with elevated C-reactive protein levels. Ann. Med. (2000) 32(8):515-518.
104. RIDKER PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation (2003) 107:363-369.
105. RIDKER PM, RIFAI N, ROSE L, BURING JE, COOK NR: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. (2002) 347:1557-1565.
106. VERMA S, WANG CH, LI SH et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 106(8):913-919.
107. SPEIDL WS, ZEINER A, NIKFARDJAM M et al.: An increase of C-reactive protein is associated with enhanced activation of endogenous fibrinolysis at baseline but an impaired endothelial fibrinolytic response after venous occlusion. J. Am. Coll. Cardiol. (2005) 45(1):30-34.
108. HRISTOV M, WEBER C: Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance J. Cell. Mol. Med. (2004) 8(4):498-508.
109. DIMMELER S, AICHER A, VASA M, MILDNER-RIHM C, ADLER K: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI3-kinase/Akt pathway, J. Clin. Invest. (2001) 108:391-397,
110. FADINI GP, MIORIN M, FACCO M, BONAMICO S, BAESSO I: Circulating endothelial progenitor cells are reduced in peripheral vascular complications of Type 2 diabetes mellitus. J. Am. Coll. Cardiol. (2005) 45(9):1449-1457.
111. BLANN AD, WOYWODT A, BERTOLINI F et al.: Circulating endothelial cells. Biomarker of vascular disease. Thromb. Haemost. (2005) 93(2):228-235.
112. FREESTONE B, LIP GYH, CHONG AY, NADAR S, LEE KW, BLANN AD: Circulating endothelial cells in atrial fibrillation with and without acute cardiovascular disease. Thromb. Haemost. (2005) 94:702-706.
113. LEE KW, LIP GY, TAYEBJEE M, FOSTER W, BLANN AD: Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes. Blood (2005) 105(2):526-532.
114. HALCOX JP, SCHENKE WH, ZALOS G et al.: Prognostic value of coronary vascular endothelial dysfunction. Circulation (2002) 106(6):653-658.
115. HASDAI D, LERMAN A: The assessment of endothelial function in the cardiac catheterisation laboratory in patients with risk factors for atherosclerotic coronary artery disease. Herz (1999) 24:544-547.
116. DREXLER H, ZEIHER AM: Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension (1991) 18(Suppl. 4):II90-II99.
117. DUFFY SJ, CASTLE SF, HARPER RW, MEREDITH IT: Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation. Circulation (1999) 100(19):1951-1957
118. RIZZONI D, PORTERI E, CASTELLANO M et al.: Vascular hypertrophy and remodeling in secondary hypertension. Hypertension (1996) 28:785-790.
119. MULVANY MJ, HANSEN PK, AALKJAER C: Direct evidence that the greater contractility of resistance vessels in spontaneously hypertensive rats is associated with a narrowed lumen, a thickened media, and an increased number of smooth muscle cell layers. Circ. Res. (1978) 43:854-864.
120. HEAGERTY AM, AALKJAER C, BUND SJ, KORSGAARD N, MULVANY MJ: Small artery structure in hypertension: dual process of remodeling and growth. Hypertension (1993) 21:391-397.
121. REDDY KG, NAIR NR, SHEEHAN HM, HODGSON JM: Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for coronary artery disease. Circulation (1994) 23:833-843.
122. GORDON JB, GANZ P, NABEL EG, FISH ZEBEDE J, MUDGE GH: Atheroscelerosis influences the vasomotor response of epicardial coronary arteries to exercise. J. Clin. Invest. (1989) 83:1946-1952.
123. SUWAIDI JA, HAMASAKI S, HIGANO ST, NISHIMURA RA, HOLMES DR Jr, LERMAN A: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation (2000) 101(9):948-954.
124. ANDERSON TJ, MEREDITH IT, YEUNG AC, FREI B, SELWYN AP, GANZ P: The effect of cholesterol lowering and antioxidant therapy on endothelial dependent coronary vasomotion. N. Engl. J. Med. (1995) 332:448-493.
125. BERDEAUX A, DUBOIS-RANDE JL, HITTINGER L: Nitrates et dysfonctionnement vasculaire coronaire d'endothélium [Nitrates and coronary vascular endothelium dysfunction.] Ann. Cardiol. Angeiol. (Paris) (1997) 46(7):391-398.
126. HOKANSON DE, SUMNER DS, STRANDNESS DE Jr: An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans. Biomed Eng. (1975) 22(1):25-29.
127. JOHNSTONE MT, CREAGER SJ, SCALES KM, CUSCO JA, LEE BK, CREAGER MA: Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation (1993) 88(6):2510-2516.
128. PANZA JA, QUYYUMI AA, CALLAHAN TS, EPSTEIN SE: Effect of antihypertensive treatment on endothelium-dependent vascular relaxation in patients with essential hypertension. J. Am. Coll. Cardiol. (1993) 21(5):1145-1151.
129. LIND L, SARABI M, MILLGARD J: Methodological aspects of the evaluation of endothelium-dependent vasodilatation in the human forearm. Clin. Physiol. (1998) 18(2):81-87.
130. WEBB DJ: The pharmacology of human blood vessels in vivo. J. Vasc. Res. (1995) 32(1):2-15.
131. TADDEI S, VIRDIS A, GHIADONI L, ULERI S, MAGAGNA A, SALVETTI A: Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension (1997) 30(6):1606-1612.
132. JOHN S, SCHLAICH M, LANGENFELD M et al.: Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation (1998) 98(3):211-216.
133. GOULD KL, MARTUCCI JP, GOLDBERG DI et al.: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation (1994) 89(4):1530-1538.
134. UREN NG, MELIN JA, DE BRUYNE B, WIJNS W, BAUDHUIN T, CAMICI PG: Relation between myocardial blood flow and the severity of coronary-artery stenosis. N. Engl. J. Med. (1994) 330(25):1782-1728.
135. PITKANEN OP, RAITAKARI OT, NIINIKOSKI H et al.: Coronary flow reserve is impaired in young men with familial hypercholesterolemia. J. Am. Coll. Cardiol. (1996) 28(7):1705-1711.
136. RAITAKARI OT, PITKANEN OP, LEHTIMAKI T et al.: In vivo low density lipoprotein oxidation relates to coronary reactivity in young men. J. Am. Coll. Cardiol. (1997) 30(1):97-102.
137. LAINE H, RAITAKARI OT, NIINIKOSKI H et al.: Early impairment of coronary flow reserve in young men with borderline hypertension. J. Am. Coll. Cardiol. (1998) 32(1):147-153.
138. CZERNIN J, BARNARD RJ, SUN KT et al.: Effect of short-term cardiovascular conditioning and low-fat diet on myocardial blood flow and flow reserve. Circulation (1995) 92(2):197-204.
139. HUGGINS GS, PASTERNAK RC, ALPERT NM, FISCHMAN AJ, GEWIRTZ H: Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation (1998)98(13):1291-1296.
140. SONKA M, LIANG W, LAUER RM: Automated analysis of brachial ultrasound image sequences: early detection of cardiovascular disease via surrogates of endothelial function. IEEE Trans. Med. Imaging (2002) 21(10):1271-1279.
141. HIJMERING ML, STROES ES, PASTERKAMP G, SIEREVOGEL M, BANGA JD, RABELINK TJ: Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis (2001)157(2):369-373.
142. SORENSEN KE, CELERMAJER DS, SPIEGELHALTER DJ et al.: Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibilty. Br. Heart J. (1995) 74:247-253.
143. CELERMAJER DS: Endothelial dysfunction; Does it matter? Is it reversible? J. Am. Coll. Cardiol. (1997) 30:325-333.
144. JOANNIDES R, HAEFELI WE, LINDER L et al.: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 91:1314-1319.
145. TAKSE B, UEHATA A, AKIMA T et al.: Endothelial-dependent flow-mediated vasodilatation in coronary and brachial arteries in suspected coronary artery disease. Am. J. Cardiol. (1998) 82:1535-1539.
146. CELERMAJER DS, SORENSEN KE, GOOCH VM et al.: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet (1992) 340(8828):1111-1115.
147. AGEWALL S, DOUGHTY RN, BAGG W et al.: Comparison of ultrasound assessment of flow-mediated dilatation in the radial and brachial artery with upper and forearm cuff positions. Clin. Physiol. (2001) 21:9-14.
148. LEESON P, THORNE S, DONALD A, MULLEN M, CLARKSON P, DEANFIELD J: Non-invasive measurement of endothelial function: effect of brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart (1997) 78:22-27.
149. UEHATA A, LIEBERMANN EH, GERHARD MD et al.: Noninvasive assessment of endothelium- dependent flow-mediated dilation of the brachial artery. Vasc. Med. (1997) 997:87-92.
150. HARDIE KL, KINLAY S, HARDY DB, WLODARCZYK J, SILBERBERG JS, FLETCHER PJ: Reproducibility of brachial ultrasonography and flow-mediated dilation (FMD) for assessing endothelial function. Aust. NZ J. Med. (1997) 27:649-652.
151. VOGEL RA CORRETTI MC, PLOTNICK GD: The effect of a single high-fat meal on endothelial function in healthy subjects. Am. J. Cardiol. (1997) 79:350-354.
152. HASHIMOTO M, AKISHITA M, ETO M et al.: Modulation of endothelium-dependent dilatation of the brachial artery by sex and menstrual cycle. Circulation (1995) 92:3431-3435.
153. CORRETTI MC, ANDERSON TJ, BENJAMIN EJ et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. (2002) 39:257-265.
154. SORENSEN KE, CELERMAJER DS, GEORGAKOPOULUS D, HATCHER G, BETTERIDGE DJ, DEANFIELD JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolaemia and is related to the lipoprotein (a) level. J. Clin. Invest. (1994) 93:50-55.
155. RAITAKARI OT, ADAMS MR, CELERMAJER DS: Effect of Lp(a) on the early functional and structural changes of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. (1999) 19(4):990-995.
156. DENG YB, WANG XF, LE GR, ZHANG QP, LI CL, ZHANG YG: Evaluation of endothelial function in hypertensive elderly patients by high-resolution ultrasonography. Clin. Cardiol. (1999) 22:705-710.
157. WATTS GF, O'BRIEN SF, SILVESTER W, MILLAR JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin. Sci. (Colch.) (1996) 91:567-573.
158. CELERMAJER DS, SORENSEN KE, SPIEGELHALTER DJ, GEORGAKOPOULOS D, ROBINSON J, DEANFIELD JE: Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. (1994) 24(2):471-476.
159. RAITAKARI OT, ADAMS MR, McCREDIE RJ, GRIFFITHS KA, CELERMAJER DS: Arterial endothelial dysfunction related to passive smoking is potentially reversible in healthy young adults. Ann. Intern. Med. (1999) 130(7):578-581.
160. TAMAI O, MATSUOKA H, ITABE H, WADA Y, KOHNO K, IMAIZUMI T: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation (1997) 95(1):76-82.
161. STROES ES, KOOMANS HA, DE BRUIN TW, RABELINK TJ: Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet (1995) 346(8973):467-471.
162. -/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels < 160 mg/dl and high-density lipoprotein cholesterol levels < 40 mg/dl. Am. J. Cardiol. (1997) 80(7):831-835.
163. SIMONS LA, SULLIVAN D, SIMONS J, CELERMAJER DS: Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis (1998) 137(1):197-203.
164. DUPUIS J, TARDIF JC, CERNACEK P, THEROUX P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation (1999) 99(25):3227-3233.
165. O'DRISCOLL G, GREEN D, TAYLOR RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation (1997) 95(5):1126-1131.
166. BRUSH JEJ, CANNON RO, SCHENKE WH et al.: Angina due to coronary micraovascular disease in hypertensive patients without left ventricular hypertrophy. N. Engl. J. Med. (1988) 319:1302-1307.
167. HASDAI D, GIBBONS RJ, HOLMES DRJ et al.: Coronary endothelial dysfunction is associated with myocardial perfusion defects. Circulation (1997) 96:3390-3395.
168. COHN JN: Arterial compliance to stratify cardiovascular risk: more precision in therapeutic decision making. Am. J. Hypertens. (2001) 14:258S-263S (Supplement).
169. MUIESAN ML, SALVETTI M, MONTEDURO C et al.: Effect of treatment on flow-dependent vasodilation of the brachial artery in essential hypertension. Hypertension (1999) 33(1 Part 2):575-580.
170. WEISS D, KOOLS JJ, TAYLOR WR: Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation (2001) 103(3):448-454.
171. RAJAGOPALAN S, KURZ S, MUENZEL T et al.: Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: contribution to alteration of vasomotor tone. J. Clin. Invest. (1996) 97:1916-1923.
172. SORESCU D, GRIENDLING KK: Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest. Heart Fail. (2002) 8(3):132-140.
173. GRIENDLING KK, ALEXANDER RW: Oxidative stress and cardiovascular disease. Circulation (1997) 96:3264-3265.
174. LUESCHER TF, VANHOUTTE PM, RAIJ L: Antihypertensive treatment normalizes decreased endothelium-dependent relaxations in rats with salt-induced hypertension. Hypertension (1987) 9(6 Part 2):III193-III197.
175. RODRIGO E, MAESO R, MUNOZ-GARCIA R et al.: Endothelial dysfunction in spontaneously hypertensive rats: consequences of chronic treatment with losartan or captopril. J. Hypertens. (1997) 15(6):613-618.
176. CREAGER MA, RODDY MA: Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension (1994) 24(4):499-505.
177. RIZZONI D, MUIESAN ML, PORTERI E et al.: Effects of long-term antihypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J. Hypertens. (1997) 15(2):197-204.
178. THYBO NK, STEPHENS N, COOPER A, AALKJAER C, HEAGERTY AM, MULVANY MJ: Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension (1995) 25(Part 1):474-481.
179. SCHIFFRIN EL, DENG LY, LAROCHELLE P: Effects of a β-blocker or a converting enzyme inhibitor on small arteries in essential hypertension. Hypertension (1994) 23:83-91.
180. SCHIFFRIN EL, DENG LY, LAROCHELLE P: Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I-converting enzyme inhibitor: comparison with effects of a β-blocker. Am. J. Hypertens. (1995) 8:229-236.
181. RUSCHITZKA F, NOLL G, LUESCHER TF: Angiotensin converting enzyme inhibitors and vascular protection in hypertension. J. Cardiovasc. Pharmacol. (1999) 34(Suppl. 1):S3-S12.
182. HORNIG B, DREXLER H: Endothelial function and bradykinin in humans. Drugs (1997) 54(Suppl. 5):42-47.
183. HORNIG B, KOHLER C, DREXLER H: Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation (1997) 95:1115-1118.
184. GRIENDLING KK, SORESCU D, USHIO-FUKAI M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. (2000) 86(5):494-501.
185. SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653-1659.
186. GHIODONI L, VIRDIS A, MAGAGNA A et al.: Effect of angiotensin II Type I receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension (2000) 35:501-506.
187. VON ZUR MUHLEN B, KAHAN T, HAGG A, MILLGARD J, LIND L: Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J. Hypertens. (2001) 19(10):1813-1818.
188. RIZZONI D, PORTERI E, DE CIUCEIS C et al.: Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Hypertension (2005) 45(4):659-665.
189. SCHIFFRIN EL, PU Q, PARK JB: Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients. Am. J. Hypertens. (2002) 15(2 Part 1):105-110.
190. TADDEI S, VIRDIS A, GHIADONI L, ULERI S, MAGAGNA A, SALVETTI A: Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension (1997) 30(6):1606-1612.
191. INTENGAN HD, SCHIFFRIN EL: Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J. Cardiovasc. Pharmacol. (2000) 35(5):763-768.
192. CHUNG NA, BEEVERS DG, LIP G: Effects of losartan versus hydrochlorothiazide on indices of endothelial damage/dysfunction, angiogenesis and tissue factor in essential hypertension. Blood Press. (2004) 13(3):183-189.
193. TZEMOS N, LIM PO, MacDONALD TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation (2001) 104(5):511-514.
194. ABIOSE AK, MANSOOR GA, BARRY M, SOUCIER R, NAIR CK, HAGER D: Effect of spironolactone on endothelial function in patients with congestive heart failure on conventional medical therapy. Am. J. Cardiol. (2004) 93(12):1564-1566.
195. MacDONALD JE, KENNEDY N, STRUTHERS AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart (2004) 90(7):765-770.
196. GERHARD M, GANZ P: How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation (1995) 92(1):5-8.
197. BUSH DE, JONES CE, BASS KM, WALTERS GK, BRUZA JM, OUYANG P: Estrogen replacement reverses endothelial dysfunction in postmenopausal women. Am. J. Med. (1998) 104:552-558.
198. McCROHON JA, WALTERS WA, ROBINSON JT et al.: Arterial reactivity is enhanced in genetic males taking high dose estrogens. J. Am. Coll. Cardiol. (1997) 29:1432-1436.
199. McCROHON JA, ADAMS MR, McCREDIE RJ et al.: Hormone replacement therapy is associated with improved arterial physiology in healthy postmenopausal women. Clin. Endocrinol. Oxf. (1996) 45:435-441.
200. SORENSEN KE, DORUP I, HERMANN AP, MOSEKILDE L: Continued hormone replacement therapy does not protect women against the age-related decline in endothelial-dependent vasomotor function. Circulation (1998) 97:1234-1238.
201. KOTHNY W, ANGERER P, STORK S, VON SCHACKY C: Short term effects of omega-3 fatty acids on the radial artery of patients with coronary artery disease. Atherosclerosis (1998) 140(1):181-186.
202. VARIN R, MULDER P, RICHARD V et al.: Exercise improves flow-mediated vasodilatation of skeletal muscle arteries in rats with chronic heart failure. Role of nitric oxide, prostanoids, and oxidant stress. Circulation (1999) 99(22):2951-2957.
203. HORNIG B, MAIER V, DREXLER H: Physical training improves endothelial function in patients with chronic heart failure. Circulation (1996) 93(2):210-214.
204. FUCHSJAGER-MAYRL G, PLEINER J, WIESINGER GF et al.: Exercise training improves vascular endothelial function in patients with Type 1 diabetes. Diabetes Care (2002) 25(10):1795-1801.
205. HAMDY O, LEDBURY S, MULLOOLY C et al.: Lifestyle modification improves endothelial function in obese subjects with the insulin resistance syndrome. Diabetes Care (2003) 26(7):2119-2125.
206. McLENACHAN JM, VITA J, FISH DR et al.: Early evidence of endothelial vasodilator dysfunction at coronary branch points. Circulation (1990) 82:1169-1173.
207. McLENACHAN JM, WILLIAMS JK, FISH RD, GANZ P, SELWYN AP: Loss of flow-mediated endothelium-dependent dilation occurs early in the development of atherosclerosis. Circulation (1991) 84:1273-1278.
208. PERTICONE F, CERAVOLO R, PUJIA A et al.: Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation (2001) 104(2):191-196.
209. HEITZER T, SCHLINZIG T, KROHN K, MEINERTZ T, MUNZEL T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation (2001) 104:2673-2678.
210. PRASAD A, ZHU J, HALCOX JP, WACLAWIW MA, EPSTEIN SE, QUYYUMI AA: Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation (2002) 106(2):184-190.
211. HIGASHI Y, SASAKI S, NAKAGAWA K, MATSUURA H, CHAYAMA K, OSHIMA T: Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am. J. Hypertens. (2001) 14(10):1038-1045.
212. CHAMBERS JC, OBEID OA, KOONER JS: Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. Arterioscler. Thromb. Vasc. Biol. (1999) 19(12):2922-2927.
213. REIDY MA, SCHWARTZ SM: A technique to investigate surface morphology and endothelial cell erplication of small arteries; a study in acute angiotensin-induced hypertension. Microvasc. Res. (1982) 24:158-167.
214. KUBO SH, RECTOR TS, BANK AJ, WILLIAMS RE, HEIFETZ SM: Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation (1991) 84(4):1589-1589.
215. FILER AD, GARDNER-MEDWIN JM, THAMBYRAJAH J et al.: Diffuse endothelial dysfunction is common to ANCA associated systemic vasculitis and polyarteritis nodosa. Ann. Rheum. Dis. (2003) 62(2):162-167.
216. CLARKSON P, MONTGOMERY HE, MULLEN MJ et al.: Exercise training enhances endothelial function in young men. J. Am. Coll. Cardiol. (1999) 33(5):1379-1385.
217. MORENO H Jr, CHALON S, URAE A et al.: Endothelial dysfunction in human hand veins is rapidly reversible after smoking cessation. Am. J. Physiol. (1998) 275(3 Part 2):H1040-H1045.
218. LERMAN A, BURNETT JC Jr, HIGANO ST, McKINLEY LJ, HOLMES DR Jr: Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation (1998) 97(21):2123-2128.
219. VERHAAR MC, HONING ML, VAN DAM T et al.: Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids. Cardiovasc. Res. (1999) 42(3):752-760.
220. CELERMAJER DS, SORENSEN KE, GEORGAKOPOULOS D et al.: Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation (1993) 88(5 Part 1):2149-2155.
221. CELERMAJER DS, ADAMS MR, CLARKSON P et al.: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. (1996) 334(3):150-154.
222. COSENTINO F, HISHIKAWA K, KATUSIC ZS, LUSCHER TF: High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 96:25-28.
223. DOSHI SN, McDOWELL IF, MOAT SJ et al.: Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. Circulation (2002) 105(1):22-26.
224. RAZA K, THAMBYRAJAH J, TOWNEND JN et al.: Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation (2000) 102(13):1470-1472.
225. WENNMALM A, BENTHIN G, EDLUND A et al.: Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ. Res. (1993) 73(6):1121-1127.
226. ZEIHER AM, DREXLER H, WOLLSCHLAGER H, JUST H: Endothelial dysfunction of the coronary microvasculature is associated with coronary blood flow regulation in patients with early atherosclerosis. Circulation (1991) 84(5):1984-1992.
227. SAWYERR AM, SMITH MS, HALL A et al.: Serum concentrations of von Willebrand factor and soluble thrombomodulin indicate alteration of endothelial function in inflammatory bowel diseases. Dig. Dis. Sci. (1995) 40(4):793-799.
228. FARD A, TUCK CH, DONIS JA et al.: Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with Type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. (2000) 20(9):2039-2044.
229. DONATELLI M, HOFFMANN E, COLLETTI I et al.: Circulating endothelin-1 levels in Type 2 diabetic patients with ischaemic heart disease. Acta Diabetol. (1996) 33(3):246-248.
230. ELIASSON M, JANSSON JH, NILSSON P, ASPLUND K: Increased levels of tissue plasminogen activator antigen in essential hypertension. A population-based study in Sweden. J. Hypertens. (1997) 15(4):349-356.
231. BREVETTI G, MARTONE VD, DE CRISTOFARO T et al.: High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb. Haemost. (2001) 85(1):63-66.
232. DAVI G, ROMANO M, MEZZETTI A et al.: Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation (1998) 97(10):953-957.
233. MILLGARD J, HAGG A, SARABI M, LIND L: Captopril, but not nifedipine, improves endothelium-dependent vasodilation in hypertensive patients. J. Hum. Hypertens. (1998) 12(8):511-516.
234. TADDEI S, VIRDIS A, GHIADONI L et al.: Effect of calcium antagonist or β blockade treatment on nitric oxide-dependent vasodilation and oxidative stress in essential hypertensive patients. J. Hypertens. (2001) 19(8):1379-1386.
235. TADDEI S, VIRDIS A, GHIADONI L et al.: Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension (2001) 37(3):943-948.
236. ON YK, KIM CH, SOHN DW et al.: Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. Korean J. Intern. Med. (2002) 17(2):131-137.
237. SCHIFFRIN EL, PARK JB, INTENGAN HD, TOUYZ RM: Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation (2000) 101(14):1653-1659.
238. ENCORE INVESTIGATORS: Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation (2003) 107(3):422-428.
239. GHIADONI L, MAGAGNA A, VERSARI D et al.: Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension (2003) 41(6):1281-1286.
240. NIELSEN FS, ROSSING P, GALL MA et al.: Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy. Scand. J. Clin. Lab. Investig. (1997) 57(5):427-434.
241. BORCEA V, MORCOS M, ISERMANN B et al.: Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus. Vasa (1999) 28(3):172-180.
242. TADDEI S, VIRDIS A, GHIADONI L, SUDANO I, SALVETTI A: Antihypertensive drugs and reversing of endothelial dysfunction in hypertension. Curr. Hypertens. Rep. (2000) 2(1):64-70.
243. LI-SAW-HEE FL, BEEVERS DG, LIP GY: Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int. J. Cardiol. (2001) 78(3):241-246.
244. SELJEFLOT I, ARNESEN H, ANDERSEN P, ASPELIN T, KIERULF P: Effects of doxazosin and atenolol on circulating endothelin-1 and von Willebrand factor in hypertensive middle-aged men. J. Cardiovasc. Pharmacol. (1999) 34(4):584-588.
245. MAKRIS TK, STAVROULAKIS GA, KRESPI PG et al.: Fibrinolytic/hemostatic variables in arterial hypertension: response to treatment with irbesartan or atenolol. Am. J. Hypertens. (2000) 13(7):783-778
246. TZEMOS N, LIM PO, MacDONALD TM: Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation (2001) 104(5):511-514.
247. MANCINI GB, HENRY GC, MACAYA C et al.: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 94(3):258-265.
248. LEIGHTON F, CUEVAS A, GUASCH V et al.: Plasma polyphenols and antioxidants, oxidative DNA damage and endothelial function in a diet and wine intervention study in humans. Drugs Exp. Clin. Res. (1999) 25(2-3):133-141.